All or excerpts from the following statement can be attributed to William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer: The Alzheimer's Association is disappointed to learn of the negative interim results from the Phase III clinical trial of Semagacestat. People with Alzheimer's urgently need more and better treatment options for this devastating, fatal brain disease. That said, the Alzheimer's Association remains optimistic about the future prospects for earlier detection of Alzheimer's, better treatments and prevention strategies... 
More...
More...